Skip to main content
. 2006 Dec 12;334(7587):242. doi: 10.1136/bmj.39041.445104.BE

Table 3.

 Cox proportional hazard model to estimate risk of completed suicide after adjustment for measured risk factors and confounders

Analysis covariates Hazard ratio* (95% CI)
Venlafaxine v citalopram 1.70 (0.76 to 3.80); 2.44 (1.12 to 5.31)†
Venlafaxine v fluoxetine 1.63 (0.74 to 3.59); 2.85 (1.37 to 5.94)†
Venlafaxine v dothiepin 1.31 (0.53 to 3.25); 2.54 (1.07 to 6.02)†
Men v women 2.15 (0.53 to 8.67)
Age at start of treatment episode:
 30-59 v 18-29 0.56 (0.17 to 1.77)
 ≥60 v 18-29 0.33 (0.07 to 1.51)
Sex-age interaction:
 Men aged 30-59 1.83 (0.38 to 8.80)
 Men aged ≥60 2.31 (0.32 to 16.47)
Overlap with other antidepressants (yes v no) 0.75 (0.15 to 3.65)
First 30 days of treatment episode (yes v no) 2.85 (1.51 to 5.39)
Duration of first prescription (≤14 v ≥15 days) 1.35 (0.55 to 3.31)
Drug history before treatment episode:
 Same antidepressant (yes v no) 0.51 (0.26 to 0.99)
 Other antidepressants ever before (yes v no) 0.56 (0.21 to 1.50)
 Other antidepressants in year before (yes v no) 2.21 (0.91 to 5.39)
No of other previous antidepressants (3 v 1 or 2) 1.00 (0.48 to 2.09)
History of antidepressant multitherapy (yes v no) 1.40 (0.59 to 3.30)
Suicidal behaviour in year before treatment episode (yes v no) 7.51 (2.82 to 19.96)
Admission to hospital for psychiatric disorder in month before treatment episode (yes v no) 2.53 (0.74 to 8.68)
Psychiatric referral in year before treatment episode (yes v no) 0.99 (0.23 to 4.32)
Psychotropic therapy in 60 days before treatment episode:
 Any psychotropics (yes v no) 1.96 (0.86 to 4.42)
 Antipsychotics (yes v no) 2.46 (1.05 to 5.80)
 Mood stabilisers (yes v no) 0.71 (0.22 to 2.34)
Any psychiatric morbidity in year before treatment episode (yes v no) 0.84 (0.39 to 1.82)
Medical history:
 Bipolar disorder (yes v no) 4.94 (1.30 to 18.84)
 Depression (yes v no) 1.15 (0.34 to 3.86)
 Mixed anxiety and depression (yes v no) 0.71 (0.33 to 1.50)
 Substance misuse (yes v no) 1.30 (0.54 to 3.13)

*Measures relative risk of completed suicide adjusted for each analysis covariate after adjustment for all other variables in model, including treatment.

†Unadjusted values.